367 related articles for article (PubMed ID: 25387477)
1. Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study.
Deodhar A; Braun J; Inman RD; van der Heijde D; Zhou Y; Xu S; Han C; Hsu B
Ann Rheum Dis; 2015 Apr; 74(4):757-61. PubMed ID: 25387477
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of golimumab in Chinese patients with active ankylosing spondylitis: 1-year results of a multicentre, randomized, double-blind, placebo-controlled phase III trial.
Bao C; Huang F; Khan MA; Fei K; Wu Z; Han C; Hsia EC
Rheumatology (Oxford); 2014 Sep; 53(9):1654-63. PubMed ID: 24729398
[TBL] [Abstract][Full Text] [Related]
3. Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study.
Braun J; Deodhar A; Inman RD; van der Heijde D; Mack M; Xu S; Hsu B
Ann Rheum Dis; 2012 May; 71(5):661-7. PubMed ID: 22012970
[TBL] [Abstract][Full Text] [Related]
4. [The safety and efficacy of golimumab in treatment of 25 patients with active ankylosing spondylitis].
Ma H; Sun F; Zhang YM; Zhang H; Zhu J; Deng XH; Zhang JL; Huang F
Zhonghua Nei Ke Za Zhi; 2017 Dec; 56(12):935-939. PubMed ID: 29202535
[No Abstract] [Full Text] [Related]
5. A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis.
Sieper J; van der Heijde D; Dougados M; Maksymowych WP; Scott BB; Boice JA; Berd Y; Bergman G; Curtis S; Tzontcheva A; Huyck S; Weng HH
Arthritis Rheumatol; 2015 Oct; 67(10):2702-12. PubMed ID: 26139307
[TBL] [Abstract][Full Text] [Related]
6. Safety and Efficacy of Golimumab Administered Intravenously in Adults with Ankylosing Spondylitis: Results through Week 28 of the GO-ALIVE Study.
Deodhar A; Reveille JD; Harrison DD; Kim L; Lo KH; Leu JH; Hsia EC
J Rheumatol; 2018 Mar; 45(3):341-348. PubMed ID: 29247154
[TBL] [Abstract][Full Text] [Related]
7. Effect of Intravenous Golimumab on Fatigue and the Relationship with Clinical Response in Adults with Active Ankylosing Spondylitis in the Phase 3 GO-ALIVE Study.
Deodhar A; Shiff NJ; Gong C; Chan EKH; Hsia EC; Lo KH; Akawung A; Kim L; Xu S; Reveille JD
Rheumatol Ther; 2023 Aug; 10(4):983-999. PubMed ID: 37322274
[TBL] [Abstract][Full Text] [Related]
8. Comparison of three enthesitis indices in a multicentre, randomized, placebo-controlled trial of golimumab in ankylosing spondylitis (GO-RAISE).
van der Heijde D; Braun J; Deodhar A; Inman RD; Xu S; Mack ME; Hsu B
Rheumatology (Oxford); 2013 Feb; 52(2):321-5. PubMed ID: 23024015
[TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of Intravenous Golimumab in Adults with Ankylosing Spondylitis: Results through 1 Year of the GO-ALIVE Study.
Reveille JD; Deodhar A; Caldron PH; Dudek A; Harrison DD; Kim L; Lo KH; Leu JH; Hsia EC
J Rheumatol; 2019 Oct; 46(10):1277-1283. PubMed ID: 30824635
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial.
Inman RD; Davis JC; Heijde Dv; Diekman L; Sieper J; Kim SI; Mack M; Han J; Visvanathan S; Xu Z; Hsu B; Beutler A; Braun J
Arthritis Rheum; 2008 Nov; 58(11):3402-12. PubMed ID: 18975305
[TBL] [Abstract][Full Text] [Related]
11. Serum biomarkers and changes in clinical/MRI evidence of golimumab-treated patients with ankylosing spondylitis: results of the randomized, placebo-controlled GO-RAISE study.
Inman RD; Baraliakos X; Hermann KA; Braun J; Deodhar A; van der Heijde D; Xu S; Hsu B
Arthritis Res Ther; 2016 Dec; 18(1):304. PubMed ID: 28031053
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period.
Braun J; Deodhar A; Dijkmans B; Geusens P; Sieper J; Williamson P; Xu W; Visvanathan S; Baker D; Goldstein N; van der Heijde D;
Arthritis Rheum; 2008 Sep; 59(9):1270-8. PubMed ID: 18759257
[TBL] [Abstract][Full Text] [Related]
13. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU;
Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810
[TBL] [Abstract][Full Text] [Related]
14. The effect of golimumab therapy on disease activity and health-related quality of life in patients with ankylosing spondylitis: 2-year results of the GO-RAISE trial.
van der Heijde D; Deodhar A; Braun J; Mack M; Hsu B; Gathany TA; Inman RD; Han C;
J Rheumatol; 2014 Jun; 41(6):1095-103. PubMed ID: 24737912
[TBL] [Abstract][Full Text] [Related]
15. Golimumab reduces sleep disturbance in patients with active ankylosing spondylitis: results from a randomized, placebo-controlled trial.
Deodhar A; Braun J; Inman RD; Mack M; Parasuraman S; Buchanan J; Hsu B; Gathany T; van der Heijde D
Arthritis Care Res (Hoboken); 2010 Sep; 62(9):1266-71. PubMed ID: 20506403
[TBL] [Abstract][Full Text] [Related]
16. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3.
Pavelka K; Kivitz A; Dokoupilova E; Blanco R; Maradiaga M; Tahir H; Pricop L; Andersson M; Readie A; Porter B
Arthritis Res Ther; 2017 Dec; 19(1):285. PubMed ID: 29273067
[TBL] [Abstract][Full Text] [Related]
17. Golimumab: in the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Oldfield V; Plosker GL
BioDrugs; 2009; 23(2):125-35. PubMed ID: 19489653
[TBL] [Abstract][Full Text] [Related]
18. Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial.
Kavanaugh A; van der Heijde D; McInnes IB; Mease P; Krueger GG; Gladman DD; Gómez-Reino J; Papp K; Baratelle A; Xu W; Mudivarthy S; Mack M; Rahman MU; Xu Z; Zrubek J; Beutler A
Arthritis Rheum; 2012 Aug; 64(8):2504-17. PubMed ID: 22378566
[TBL] [Abstract][Full Text] [Related]
19. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study.
Park W; Yoo DH; Jaworski J; Brzezicki J; Gnylorybov A; Kadinov V; Sariego IG; Abud-Mendoza C; Escalante WJ; Kang SW; Andersone D; Blanco F; Hong SS; Lee SH; Braun J
Arthritis Res Ther; 2016 Jan; 18():25. PubMed ID: 26795209
[TBL] [Abstract][Full Text] [Related]
20. The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial.
Braun J; Baraliakos X; Hermann KG; Deodhar A; van der Heijde D; Inman R; Beutler A; Zhou Y; Xu S; Hsu B
Ann Rheum Dis; 2014 Jun; 73(6):1107-13. PubMed ID: 23644549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
